SNX-2112选择性结合到HSP90α和HSP90β的ATP结合袋中,Ka分别为30 nM和30 nM,比17-AAG更有效。
SNX-2112 (PF-04928473) selectively binds to the ATP pocket of HSP90α and HSP90β with Ka of 30 nM and 30 nM, uniformly more potent than 17-AAG.
0-500 nM
20或40 mg/kgSNX-5422 口服处理,每周3次,一共3周。
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Chandarlapaty S, et al, Clin Cancer Res, 2008, 14(1), 240-248.
[2] Thomas Bachleitner-Hofmann et al. Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition Clin Cancer Res January 1, 2011 17; 122
[3] Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.Clin Cancer Res. 2011 Nov 1;17(21):6831-9. Epub 2011 Sep 9.
分子式 C23H27F3N4O3 |
分子量 464.48 |
CAS号 908112-43-6 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO ≥90 mg/mL |
Water <1 mg/mL |
Ethanol 1 mg/mL |
体内溶解度
NCT02612285 | Cancer | Drug: SNX-5422 | Esanex Inc. | Phase 2 | 2016-03-01 | 2016-11-03 |
NCT02914327 | Cancer | Drug: SNX-5422 plus ibrutinib | Esanex Inc. | Phase 1 | 2017-02-02 | 2017-02-13 |
NCT02973399 | Cancer | Drug: SNX-5422 plus ibrutinib | Esanex Inc. | Phase 1 | 2017-02-07 | 2017-02-13 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们